Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Arch Physiol Biochem ; 128(5): 1283-1289, 2022 Oct.
Article in English | MEDLINE | ID: mdl-32447998

ABSTRACT

Context: Studies have shown that cardiac triglyceride accumulation and impaired Na+-K+-ATPase activity are linked to diabetes- related cardiovascular disease, particularly in women.Objectives: We hypothesised that allopurinol (ALL) and valproic acid (VPA) treatment would improve cardiac triglyceride and Na+-K+-ATPase activity independent of circulating aldosterone in Combined Oral Contraceptive (COC)-induced dysglycemiaMaterials and methods: Rats received COC (1.0 µg ethinylestradiol and 5.0 µg levonorgestrel; po) with or without ALL (1 mg; po) and VPA (20 mg; po) for 6 weeks.Results: COC-treatment led to impaired glucose tolerance, accumulated abdominal fat, dyslipidemia, elevated plasma MDA, PAI-1 and aldosterone levels and also reduced plasma nitric oxide bioavailability and cardiac Na+-K+-ATPase activity. However, either ALL or VPA treatment ameliorated these alterations comparably independent of elevated aldosterone levelDiscussion and conclusion: Our results suggest that either ALL or VPA would improve cardiac TG and Na+-K+-ATPase activity comparably in COC-treated rats, regardless of circulating aldosterone level.


Subject(s)
Glucose Intolerance , Insulin Resistance , Adenosine Triphosphatases , Aldosterone , Allopurinol/pharmacology , Animals , Contraceptives, Oral, Combined , Female , Humans , Levonorgestrel , Nitric Oxide , Plasminogen Activator Inhibitor 1/metabolism , Rats , Rats, Wistar , Sodium-Potassium-Exchanging ATPase , Triglycerides , Valproic Acid/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...